This week, we will discuss the fresh-off-the-press KDIGO guidelines on Diabetes. RAS Blockade and SGLT2i, needless to say - but is there more? There is. Read on as we break it down for you.
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.